Skip to content
Search

Latest Stories

O’Briens Pharmacy Group disposes of Blackpool site after strategic review

O’Briens Pharmacy Group disposes of Blackpool site after strategic review

The popular Blackpool pharmacy business has been acquired by a first-time buyer

O’Briens Pharmacy Group has sold Bispham Pharmacy as part of a strategic review of its nine-site portfolio, now reduced to eight, across the Fylde coast region.

Christie and Co, the property adviser, recently announced that the group’s popular Blackpool pharmacy business has been acquired by first-time buyer, Arif Bhuriya.


Bispham Pharmacy, which dispenses around 4,500 items per month, is situated in the heart of Bispham’s commercial centre, opposite a bustling shopping area. The community pharmacy has been in this location since February 2021, following a minor contract relocation.

O'Briens Pharmacy Group provides pharmacy services across Fleetwood, Thornton-Cleveleys, Bispham, Burscough, Liverpool, and surrounding areas.

Aisling O’Brien, owner of O’Briens Pharmacy, explained the rationale behind selling the Bispham site: “When we had a strategic review of our group, we saw Bispham as an ideal site to dispose of, knowing it would fare much better in the current climate as an owner-operated site.

“Naturally, we called Christie and Co and, whilst there was a good deal of interest in the site, it was pleasing to do the deal with Arif whom I am familiar with as a fellow LPC member. We wish him all the very best with the business in the future.”

Bhuriya, the new owner, plans to build on the pharmacy’s steady growth, particularly following the closure of a nearby Lloyds Pharmacy in Sainsbury’s last year. He aims to further increase item numbers while maintaining a focus on high levels of customer service and service delivery.

Having finally acquired his first pharmacy business after searching for a couple of years, Arif expressed his excitement:

“Bispham was an area which I am familiar with so when I saw the opportunity hit the market, I knew that it was a site that I could take to the next level. The hard work starts now but I’d like to thank Aisling O’Brien for all her help in working towards a successful sale and I am excited to start work on my plans for the business and the people of Bispham.”

Jon Booth, Director of Pharmacy at Christie and Co, who managed  the confidential sales process, highlighted the nature of the deal: “Whilst this deal was not without the usual challenges around funding and property matters, it is very much the type of deal we have seen in volume across the Northwest this year.”

Booth believes that as an owner-operator, Arif can identify improvements and make changes by being directly involved in the daily operations of the pharmacy, delivering first-class service to local patients.

Craig Dickson, Director at Christie Finance, who assisted Arif in securing the funding, is confident that Arif will be hands-on in running the pharmacy, and the business will thrive under his ownership.

“Arif had been looking to acquire his first pharmacy for some time and, after a few false starts, he identified Bispham as an ideal opportunity moving forward.

“I met with him, explained the funding process, then put together a pack of supporting information for our lender contacts and quickly secured excellent terms. Arif will be very much hands-on being the owner pharmacist and I’m sure the business will go from strength to strength,” Dickson said.

The sale price of Bispham Pharmacy was not disclosed.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less